US equities |
GOOGL $282.50 ▼-13.05% GOOG $280.18 ▼-12.96% MSFT $526.54 ▼-0.84% META $626.72 ▲+2.32% MU $934.20 ▼-4.99% NVDA $212.82 ▼-1.19% AMZN $244.66 ▼-3.91% AAPL $349.71 ▲+1.71%
FinancialContent

Articles published by Definium Therapeutics, Inc.

News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics, Inc. Announces Proposed Public Offering
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX
News headline image
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
From Definium Therapeutics, Inc.
Via Business Wire
Tickers DFTX